Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer

The introduction of serum Prostate Specific Antigen (PSA) testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer. Recognition that PSA testing has caused over diagnosis and over treatment of prostate cancer has g...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahoo, Debashis, Wei, Wei, Auman, Heidi, Hurtado-Coll, Antonio, Carroll, Peter R., Fazli, Ladan, Gleave, Martin E., Lin, Daniel W., Nelson, Peter S., Simko, Jeff, Thompson, Ian M., Leach, Robin J., Troyer, Dean A., True, Lawrence D., McKenney, Jesse K., Feng, Ziding, Brooks, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814231/
https://www.ncbi.nlm.nih.gov/pubmed/29464091
http://dx.doi.org/10.18632/oncotarget.23973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814231/
https://www.ncbi.nlm.nih.gov/pubmed/29464091
http://dx.doi.org/10.18632/oncotarget.23973

Ejemplares similares